These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 25336189)

  • 1. Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.
    Kawasumi M; Bradner JE; Tolliday N; Thibodeau R; Sloan H; Brummond KM; Nghiem P
    Cancer Res; 2014 Dec; 74(24):7534-45. PubMed ID: 25336189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-Hydroxynonenal induces G2/M phase cell cycle arrest by activation of the ataxia telangiectasia mutated and Rad3-related protein (ATR)/checkpoint kinase 1 (Chk1) signaling pathway.
    Chaudhary P; Sharma R; Sahu M; Vishwanatha JK; Awasthi S; Awasthi YC
    J Biol Chem; 2013 Jul; 288(28):20532-46. PubMed ID: 23733185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
    Cui Y; Palii SS; Innes CL; Paules RS
    Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
    Pabla N; Huang S; Mi QS; Daniel R; Dong Z
    J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.
    Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Kovar P; Li G; Wang G; Tao ZF; Tong Y; Lin NH; Sham HL; Wang JY; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2006 Dec; 119(12):2784-94. PubMed ID: 17019715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
    Demidova AR; Aau MY; Zhuang L; Yu Q
    J Biol Chem; 2009 Feb; 284(7):4132-9. PubMed ID: 19060337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol analogue (E)-8-acetoxy-2-[2-(3,4-diacetoxyphenyl)ethenyl]-quinazoline induces G₂/M cell cycle arrest through the activation of ATM/ATR in human cervical carcinoma HeLa cells.
    Kim JY; Choi HE; Lee HH; Shin JS; Shin DH; Choi JH; Lee YS; Lee KT
    Oncol Rep; 2015 May; 33(5):2639-47. PubMed ID: 25812484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage.
    Helt CE; Cliby WA; Keng PC; Bambara RA; O'Reilly MA
    J Biol Chem; 2005 Jan; 280(2):1186-92. PubMed ID: 15533933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconstitution of human claspin-mediated phosphorylation of Chk1 by the ATR (ataxia telangiectasia-mutated and rad3-related) checkpoint kinase.
    Lindsey-Boltz LA; Serçin O; Choi JH; Sancar A
    J Biol Chem; 2009 Nov; 284(48):33107-14. PubMed ID: 19828454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
    Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
    Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
    Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
    Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperoxia activates the ATR-Chk1 pathway and phosphorylates p53 at multiple sites.
    Das KC; Dashnamoorthy R
    Am J Physiol Lung Cell Mol Physiol; 2004 Jan; 286(1):L87-97. PubMed ID: 12959929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs.
    Toledo LI; Murga M; Fernandez-Capetillo O
    Mol Oncol; 2011 Aug; 5(4):368-73. PubMed ID: 21820372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link-generating agents in vitro and in vivo.
    Wang HC; Lee AY; Chou WC; Wu CC; Tseng CN; Liu KY; Lin WL; Chang FR; Chuang DW; Hunyadi A; Wu YC
    Mol Cancer Ther; 2012 Jul; 11(7):1443-53. PubMed ID: 22532598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
    Biskup E; Naym DG; Gniadecki R
    J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
    Myers K; Gagou ME; Zuazua-Villar P; Rodriguez R; Meuth M
    PLoS Genet; 2009 Jan; 5(1):e1000324. PubMed ID: 19119425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases.
    Cortez D
    J Biol Chem; 2003 Sep; 278(39):37139-45. PubMed ID: 12847089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
    Jackson CB; Noorbakhsh SI; Sundaram RK; Kalathil AN; Ganesa S; Jia L; Breslin H; Burgenske DM; Gilad O; Sarkaria JN; Bindra RS
    Cancer Res; 2019 Sep; 79(17):4331-4338. PubMed ID: 31273061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction.
    Xiao G; Kue P; Bhosle R; Bargonetti J
    Cell Cycle; 2015; 14(5):744-54. PubMed ID: 25565400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.